IceCure's ProSense Cryoablation Study Gains IRB Approval for Breast Cancer Treatment
Event summary
- West Cancer Center received IRB approval for IceCure's ChoICE Study on August 20, 2026.
- The study will evaluate ProSense cryoablation for low-risk breast cancer in patients aged 70+.
- 30 sites will enroll 400 patients, with dual pathways for trial and commercial treatment.
- ProSense is FDA-cleared for local treatment of low-risk breast cancer with endocrine therapy.
The big picture
IceCure's ChoICE Study represents a strategic push to solidify cryoablation as a mainstream breast cancer treatment. The FDA's prior approval of ProSense highlights the growing acceptance of minimally invasive alternatives to surgery, particularly for low-risk patients. The dual enrollment model—combining trial and commercial pathways—could accelerate adoption while generating critical real-world data.
What we're watching
- Clinical Validation
- Whether the ChoICE Study will reinforce ProSense's efficacy in real-world settings.
- Market Adoption
- The pace at which cryoablation gains traction as a minimally invasive alternative to surgery.
- Regulatory Expansion
- How the study results may influence FDA approval for broader patient populations.
Related topics